Among patients with ovarian cancer, those who had “high” IL-6R expression showed significantly worse PFS than those who had “low” or negative IL-6R expression (PFS, 23.8 vs. 32.3 months, P = 0.0029, Fig. 1B). This evidence concerns the gene IL6R and ovarian carcinoma.